![]() |
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of mal
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
More... |
| All times are GMT -7. The time now is 03:33 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021